 |
|
Glucosamine-like supplement inhibits multiple sclerosis, type 1 diabetes
May 15, 2007A glucosamine-like dietary supplement has been found to suppress the damaging autoimmune response seen in multiple sclerosis and type 1 diabetes mellitus, according to University of California, Irvine health sciences researchers.
In studies on mice, Dr. Michael Demetriou and colleagues with the UC Irvine Center for Immunology found that N-acetylglucosamine (GlcNAc), which is similar but more effective than the widely available glucosamine, inhibited the growth and function of abnormal T-cells that incorrectly direct the immune system to attack specific tissues in the body, such as brain myelin in MS and insulin-producing cells of the pancreas in diabetes. Study results appear on the online version of the Journal of Biological Chemistry.
"This finding shows the potential of using a dietary supplement to help treat autoimmune diseases," said Demetriou, an assistant professor of neurology, and microbiology and molecular genetics. "Most importantly, we understand how this sugar-based supplement inhibits the cells that attack the body, making metabolic therapy a rational approach to prevent or treat these debilitating diseases."
The UC Irvine study defines how metabolic therapy with the sugar GlcNAc and other related nutrients modifies the growth and autoimmune activitiy of T-cells. Virtually all proteins on the surface of cells, including T-cells, are modified with complex sugars of variable lengths and composition. Recent studies have shown that changes in these sugars are often associated with T-cell hyperactivity and autoimmune disease.
In mouse models of both MS and type 1 diabetes, Demetriou and colleages found that GlcNAc prevented this hyperactivity and autoimmune response by increasing sugar modifications to the T-cell proteins. This therapy normalized T-cell function and prevented development of paralysis in MS and high blood glucose levels in type 1 diabetes.
This study comes on the heels of others showing the potential of GlcNAc in humans. One previous clinical study reported that 8 of 12 children with treatment-resistant autoimmune inflammatory bowel disease improved significantly following two years of treatment with GlcNAc. No significant adverse side effects were noted.
"Together, these findings identify metabolic therapy using dietary supplements such as GlcNAc as potential treatments for autoimmune diseases." Demetriou said. "Excitement for this treatment strategy stems from the novel mechanism for affecting T-cell function and autoimmunity and the availability and simplicity of its use. However, additional studies in humans will be required to assess the full potential of this therapeutic approach."
Autoimmune diseases such as MS and type 1 diabetes mellitus result from poorly understood interactions between inherited genetic risk and environmental exposure. MS results in neurological dysfunction, while uncontrolled blood glucose in type 1 diabetes can lead to damage of multiple organs.
Ani Grigorian, Sung-Uk Lee, Wenqiang Tian, I-Ju Chen and Guoyan Gao of UC Irvine and Richard Mendelsohn and James W. Dennis of the Samuel Lunenfeld Research Institute in Toronto participated in the study, which was funded by the National Institutes of Health, the National Multiple Sclerosis Society, the Juvenile Diabetes Research Foundation, the Wadsworth Foundation and the Canadian Institutes for Health Research.
University of California, Irvine
The UC Irvine study defines how metabolic therapy with the sugar GlcNAc and other related nutrients modifies the growth and autoimmune activitiy of T-cells. Virtually all proteins on the surface of cells, including T-cells, are modified with complex sugars of variable lengths and composition. Recent studies have shown that changes in these sugars are often associated with T-cell hyperactivity and autoimmune disease.
In mouse models of both MS and type 1 diabetes, Demetriou and colleages found that GlcNAc prevented this hyperactivity and autoimmune response by increasing sugar modifications to the T-cell proteins. This therapy normalized T-cell function and prevented development of paralysis in MS and high blood glucose levels in type 1 diabetes.
This study comes on the heels of others showing the potential of GlcNAc in humans. One previous clinical study reported that 8 of 12 children with treatment-resistant autoimmune inflammatory bowel disease improved significantly following two years of treatment with GlcNAc. No significant adverse side effects were noted.
"Together, these findings identify metabolic therapy using dietary supplements such as GlcNAc as potential treatments for autoimmune diseases." Demetriou said. "Excitement for this treatment strategy stems from the novel mechanism for affecting T-cell function and autoimmunity and the availability and simplicity of its use. However, additional studies in humans will be required to assess the full potential of this therapeutic approach."
Autoimmune diseases such as MS and type 1 diabetes mellitus result from poorly understood interactions between inherited genetic risk and environmental exposure. MS results in neurological dysfunction, while uncontrolled blood glucose in type 1 diabetes can lead to damage of multiple organs.
Ani Grigorian, Sung-Uk Lee, Wenqiang Tian, I-Ju Chen and Guoyan Gao of UC Irvine and Richard Mendelsohn and James W. Dennis of the Samuel Lunenfeld Research Institute in Toronto participated in the study, which was funded by the National Institutes of Health, the National Multiple Sclerosis Society, the Juvenile Diabetes Research Foundation, the Wadsworth Foundation and the Canadian Institutes for Health Research.
University of California, Irvine
Autoimmune Response Current Events and Autoimmune Response News RSSNew link found between osteoporosis and coeliac disease
People with coeliac disease may develop osteoporosis because their immune system attacks their bone tissue, a new study has shown.
UM scientists pinpoint critical molecule to celiac disease, possibly other autoimmune disorders
It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes.
Device Protects Transplanted Pancreatic Cells from the Immune System
Scientists at Burnham Institute for Medical Research (Burnham) and the University of California San Diego (UC San Diego) School of Medicine have demonstrated in mice that transplanted pancreatic precursor cells are protected from the immune system when encapsulated in polytetrafluorethylene (PTFE).
MDC researchers prevent virus induced myocarditis
Life-threatening cardiac arrhythmia can be a consequence of myocarditis - an inflammation of the cardiac muscle that can be caused by the Coxsackievirus.
Don't be a stranger to yourself
One of the most important tasks of the immune system is to identify what is foreign and what is self. If this distinction fails, then the body's own structures will be attacked, the result of which could be an autoimmune disease such as diabetes mellitus type 1 or multiple sclerosis.
UCSF finds potential new antibody treatment for autoimmune diseases
Scientists at UCSF have discovered an abnormality in a patient's immune system that may lead to safer therapies for autoimmune diseases such as rheumatoid arthritis and colitis, as well as potential new ways to treat transplant rejection.
New scientific knowledge on juvenile diabetes
Finnish scientists have reported a breakthrough in the attempts to understand the development of type 1 diabetes. They discovered disturbances in lipid and amino acid metabolism in children who later progressed to type 1 diabetes, also known as juvenile diabetes.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
Accumulated bits of a cell's own DNA can trigger autoimmune disease
A security system wired within every cell to detect the presence of rogue viral DNA can sometimes go awry, triggering an autoimmune response to single-stranded bits of the cell's own DNA, according to a report in the August 22nd issue of the journal Cell, a Cell Press publication.
Study Underway to Find an Alternative Cure for Crohn's Disease and Ulcerative Colitis
Two research studies evaluating dietary changes and complementary medicine for the treatment of inflammatory bowel diseases (IBD) have been launched at Rush University Medical Center.
More Autoimmune Response Current Events and Autoimmune Response News Articles
|
Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA.(Research): An article from: Environmental Health Perspectives by Jean C. Pfau (Author), Jami J. Sentissi (Author), Greg Weller (Author), Elizabeth A. Putnam (Author) This digital document is an article from Environmental Health Perspectives, published by Thomson Gale on January 1, 2005. The length of the article is 6015 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA.(Research) Author: Jean C. Pfau Publication: Environmental Health Perspectives (Magazine/Journal) Date: January 1, 2005 Publisher: Thomson Gale Volume: 113 Issue: 1 Page: 25(6) Distributed by Thomson... | |
 |
Immune Regulation and Immunotherapy in Autoimmune Disease by Jingwu Zhang (Editor) This volume will review the most recent advances in the understanding of cellular and molecular mechanisms for immune responses and immune regulation. Chapters in the first portion of this book will discuss the theoretical basis for current immunotherapies for autoimmune diseases. The second portion of the book will provide an updated review on the research behind the clinical trials/immunotherapies (e.g. T-cell vaccination, antibody therapy, etc.) in the areas of autoimmune diseases by the principal investigators of these studies. These chapters will discuss clinical and basic research as well as immunological data in the context of cellular and molecular mechanisms of the therapies. The book will finish with chapters by leaders in the field who will provide expert views on challenges... |
 |
Biologic and Gene Therapy of Autoimmune Disease (Current Directions in Autoimmunity) by C. Garrison Fathman (Editor) The clinical management of autoimmune diseases has proven to be extremely difficult. Current therapies focus on trying to alleviate symptoms, but fail to correct the fundamental immune defects that lead to pathology. To achieve this goal, it is necessary to understand much of the biology of antigen presentation, lymphocyte activation and the effects of cytokines. The articles in this book provide an up-to-date review of current innovative therapies using both biologic and gene therapy for the treatment of selected autoimmune diseases. Therapeutical approaches discussed include oral tolerance, the use of anti-CD4 monoclonal antibodies, IL-10 and anti-TNFa antibodies, DNA vaccination, and gene therapy applied to organ-specific autoimmune disease. Although some of these techniques are still... |
 |
T Cell Subsets in Infectious and Autoimmune Diseases - Symposium No. 195 by CIBA Foundation Symposium (Author) Mature T cells are classified on the basis of their surface marker proteins, such as CD4 and CD8. CD4+ and CD8+ cells recognize antigens associated with major histocompatibility complex class II and class I molecules, respectively, and they can both be further classified into subgroups. The division of CD4+ T cells into T helper 1 (Th1) and Th2 cells is based on the secretion of distinct patterns of cytokines, and the resulting polarized Th1 and Th2 responses play different roles in protection and the promotion of different immunopathological reactions. In contrast, CD8+ T cells are strongly cytotoxic; however, they can also secrete Th1-like or Th2-like cytokine profiles. This suggests that there is an increasingly complex network of cytokine regulatory patterns which are produced in... |
 |
Cytokines and Chemokines in Autoimmune Disease (Advances in Experimental Medicine and Biology) by Pere Santamaria (Editor), Peter Hackett (Editor) Univ. of Calgary, Canada. Text provides current knowledge on the role of cytokines and chemokines in autoimmunity by focusing on prevalent organ-specific or systemic autoimmune disorders that affect humans. Discusses such topics as receptors and their genes, immunoregulation, and tissue destruction. |
|
Autoimmunoregulation and Autoimmune Disease (Concepts in Immunopathology) by J. M. Cruse (Author), R. E. Lewis (Editor) | |
 |
The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders by Elaine A. Moore (Author), Dr. Yash P. Agrawal (Foreword), Samantha Wilkinson (Foreword) Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies,... |
 |
Cytokines and Autoimmune Diseases by Vijay K. Kuchroo (Editor), Nora Sarvetnick (Editor), David A. Hafler (Editor), Lindsay B. Nicholson (Editor) Harvard Medical School, Boston, MA. Features state-of-the-art review of the role of cytokines in the induction and regulation of autoimmunity. Includes an examination of the role of cytokines in a variety of diseases and indication of the potential of cytokine modulation in the treatment of autoimmune diseases. DNLM: Autoimmune Diseases--immunology. |
 |
Epitope Recognition Since Landsteiner's Discovery by M. Eibl (Editor), W.R. Mayr (Editor), G.J. Thorbecke (Editor) Karl Landsteiner is best known for his discovery of the human blood goups. The revolutionary discoveries of this brilliant scientist in other fields have not received the recognition they deserve. His demonstration that poliomyelitis is transmissable showed the way of modern virology. His studies opening the field for epitope recognition, which he himself considered his main achievement, laid the foundation for research ongoing in our days. This book with its outstanding contributors is but a small tribute to this visionary scientist. |
 |
Interferon: The 50th Anniversary (Current Topics in Microbiology and Immunology) by Paula M. Pitha (Author), Paula M. Pitha (Editor) Over the last half of century interferon (IFN), originally discovered as an antiviral protein, has developed from an inhibitor of viral replication to a major force in the antiviral response. Initially studied only by few virologists, IFN was generally considered as a poorly defined protein of limited importance. The development of molecular techniques lead to the identification of a family of IFN genes and has shown an unexpected complexity of type I IFN genes and their expression. Presently, some aspects of the of the pathogen mediated induction of IFN gene expression are understood at molecular level, while others are still at the stage of description. Both Toll like receptors and cytoplasmic RNA helicases were shown to recognize viral nucleic acids and the basis of a distinct... |
| © 2009 BrightSurf.com |